Biotia Raises $9M Series A to Expand AI-Powered Clinical Metagenomics | VeilStrat

Biotia Secures $9 Million Series A

Biotia, a New York City-based clinical metagenomics company, has raised $9 million in Series A funding. The round was announced on October 1, 2026, and included participation from a broad syndicate of investors.

What Biotia Does

Biotia pairs pathogen genomics with artificial intelligence to diagnose challenging and chronic infections. A spinout of the Jacobs Technion-Cornell Institute at Cornell Tech, the company operates a high-complexity CLIA-certified laboratory.

Its flagship offering, the BIOTIA-ID Urine Test, is designed for recurrent and complicated urinary tract infections and is available to physicians and patients in all 50 US states. The company is also expanding its test menu into women's health and orthopedic diagnostics.

Investors

The Series A round included participation from:

Continuum Health Ventures
Leawood Venture Capital
I-Lab Angels
Convergent Ventures
EGB Capital
Red Bear Ventures
DigitalDx Ventures
Cloquet Capital Partners
Red Bear Angels
Tim Barry
Clive Fields

No lead investor was disclosed for the round.

Strategic Partnerships

Biotia's partners and collaborators include Mayo Clinic, Hospital for Special Surgery, and NASA. These relationships underscore the company's position at the intersection of clinical diagnostics, genomics, and advanced computing.

Market Positioning

Biotia operates in the clinical metagenomics space, where the combination of pathogen genomics and artificial intelligence is used to address infections that are difficult to diagnose through conventional methods. Its CLIA-certified laboratory and nationwide availability of the BIOTIA-ID Urine Test give it an operational footprint that spans laboratory services and diagnostic testing.

The company's expansion into women's health and orthopedic diagnostics signals a broader platform strategy beyond its initial focus on urinary tract infections.

Acquisition Angle

For acquirers in diagnostics, life sciences tools, or healthcare AI, Biotia represents a tuck-in or platform opportunity with several attractive attributes:

Regulatory and operational infrastructure: A high-complexity CLIA-certified laboratory is a meaningful barrier to entry and a valuable asset for any acquirer looking to scale clinical testing.
Commercial reach: The BIOTIA-ID Urine Test is available in all 50 US states, providing an existing distribution channel for additional tests.
Expanding menu: Movement into women's health and orthopedic diagnostics suggests a pipeline that can be cross-sold through existing physician relationships.
Blue-chip collaborators: Partnerships with Mayo Clinic, Hospital for Special Surgery, and NASA lend credibility and may open doors to further clinical validation and research collaborations.
AI differentiation: The integration of artificial intelligence with pathogen genomics positions Biotia within the broader trend of computational approaches to diagnostics.

What to Watch

With fresh Series A capital, Biotia is positioned to advance its test menu expansion and deepen its commercial presence. The absence of a disclosed lead investor means the round was likely syndicated across a group of funds and angels, which may influence governance and future financing dynamics.

For strategic acquirers, the key questions will center on reimbursement traction for the BIOTIA-ID Urine Test, the pace of menu expansion into women's health and orthopedics, and the scalability of the company's laboratory operations.

Summary

Company: Biotia
Headquarters: New York City
Round: Series A
Amount: $9 million
Date: October 1, 2026
Lead Investor: Not disclosed
Investors: Continuum Health Ventures, Leawood Venture Capital, I-Lab Angels, Convergent Ventures, EGB Capital, Red Bear Ventures, DigitalDx Ventures, Cloquet Capital Partners, Red Bear Angels, Tim Barry, Clive Fields
Focus: Clinical metagenomics, AI-powered diagnostics, BIOTIA-ID Urine Test, expansion into women's health and orthopedic diagnostics